Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOSES: DOACs vs Antiplatelets for Secondary Stroke Prevention
NCT03961334Phase 3Recruiting
- Sponsor
- University of Zurich
- Start
- Dec 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of dabigatran, apixaban, edoxaban in ischemic stroke, sponsored by University of Zurich. Started Dec 2019; status: recruiting.
02
Drugs
dabigatranapixabanedoxaban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03961334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961334.